Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00072449 · OUTCOME

Radiographic Response

Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma · Source last updated 2013-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
1 month, 2 months and then q3months

What was measured

it at any time point patient progresses no more scans are required, patient is off study

Groups in this outcome

Rituximab Monotherapy

Rituximab administered at a dose of 375mg/m2 as a single IV infusion every week for up to 8 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Rituximab Monotherapy11

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Rituximab Monotherapy4Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        4
denoms
  1. counts
    1. group Id
      OG000
      value
      11
    units
    Participants
description
it at any time point patient progresses no more scans are required, patient is off study
groups
  1. description
    Rituximab administered at a dose of 375mg/m2 as a single IV infusion every week for up to 8 weeks
    id
    OG000
    title
    Rituximab Monotherapy
param Type
NUMBER
reporting Status
POSTED
time Frame
1 month, 2 months and then q3months
title
Radiographic Response
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice